232 related articles for article (PubMed ID: 15272577)
1. [Significance of current bio- and molecular-markers in urological cancers].
Shimazui T; Akaza H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers in urologic cancer.
Javadpour N
Urology; 1980 Aug; 16(2):127-36. PubMed ID: 6157242
[No Abstract] [Full Text] [Related]
3. [Tumor markers in urological malignancies].
Kuriyama M
Nihon Rinsho; 1996 Jun; 54(6):1631-6. PubMed ID: 8691621
[TBL] [Abstract][Full Text] [Related]
4. [Related biomarkers in the diagnosis of prostate cancer].
Xu YM; Liu HZ
Zhonghua Nan Ke Xue; 2015 Oct; 21(10):937-40. PubMed ID: 26665686
[TBL] [Abstract][Full Text] [Related]
5. Tumour markers in urology: aids in cancer diagnosis and management.
Wahren B
Urol Res; 1979 Jun; 7(2):57-67. PubMed ID: 89748
[No Abstract] [Full Text] [Related]
6. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
[TBL] [Abstract][Full Text] [Related]
7. Serum and cellular biologic tumor markers in patients with urologic cancer.
Javadpour N
Hum Pathol; 1979 Sep; 10(5):557-68. PubMed ID: 93569
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review.
Nicholson BD; Jones NR; Protheroe A; Joseph J; Roberts NW; Van den Bruel A; Fanshawe TR
Cancer Epidemiol; 2019 Apr; 59():15-21. PubMed ID: 30658216
[TBL] [Abstract][Full Text] [Related]
9. [Tumor marker in urology].
Shimazaki J; Ito H; Miyauchi T; Maruoka M; Isaka S; Masukagami T; Ando K
Gan No Rinsho; 1983 May; 29(6):684-92. PubMed ID: 6192269
[TBL] [Abstract][Full Text] [Related]
10. [Metastasis and markers].
Trinchieri A; Rovera F; Longo G; Del Nero A; Zanetti G; Austoni E
Arch Ital Urol Nefrol Androl; 1992 Mar; 64(1):27-30. PubMed ID: 1373913
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers of urinary tract carcinoma].
Kikuchi H
Rinsho Byori; 2004 Apr; 52(4):371-80. PubMed ID: 15164607
[TBL] [Abstract][Full Text] [Related]
12. [Clinical significance of expression of PSA, hK2, PSMA in the peripheral blood of patients with prostate cancer].
Cui WG; Zhao H; Song YZ; Zhang J; Zhang LG; Shi JD; Qiang WM
Zhonghua Zhong Liu Za Zhi; 2004 Aug; 26(8):479-81. PubMed ID: 15555338
[TBL] [Abstract][Full Text] [Related]
13. [The clinical usefulness of urinary basic fetoprotein (BFP) in patients with urological malignancies].
Tsujii T; Yonese J; Kojima S; Tari K; Ishii M; Seino Y
Nihon Hinyokika Gakkai Zasshi; 1990 Jun; 81(6):829-34. PubMed ID: 1698231
[TBL] [Abstract][Full Text] [Related]
14. [Human placental alkaline phosphatase (hPLAP) is the most frequently elevated serum marker in testicular cancer].
Neumann A; Keller T; Jocham D; Doehn C
Aktuelle Urol; 2011 Sep; 42(5):311-5. PubMed ID: 21809268
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific membrane antigen: current and future utility.
Gregorakis AK; Holmes EH; Murphy GP
Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
[TBL] [Abstract][Full Text] [Related]
16. [Use of radioimmunoanalysis for tumor markers in the diagnosis of carcinoma of the testes and prostate].
Kausitz J
Bratisl Lek Listy; 1988 Oct; 89(10):715-24. PubMed ID: 2463063
[No Abstract] [Full Text] [Related]
17. Clinical applications of recent molecular advances in urologic malignancies: no longer chasing a "mirage"?
Netto GJ
Adv Anat Pathol; 2013 May; 20(3):175-203. PubMed ID: 23574774
[TBL] [Abstract][Full Text] [Related]
18. HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.
Barresi V; Ieni A; Cardia R; Licata L; Vitarelli E; Reggiani Bonetti L; Tuccari G
APMIS; 2016 Mar; 124(3):188-93. PubMed ID: 26590121
[TBL] [Abstract][Full Text] [Related]
19. Next revolution in molecular theranostics: personalized medicine for urologic cancers.
Aoun F; Kourie HR; Artigas C; Roumeguère T
Future Oncol; 2015; 11(15):2205-19. PubMed ID: 26235183
[TBL] [Abstract][Full Text] [Related]
20. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
